Endovascular Treatment With Versus Without Intravenous rhTNK-tPA in Stroke

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 550 participants.

Also called NCT04733742

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 550 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04733742
Other papers using this trial's data
  • Effect of Baseline ASPECTS on Tenecteplase Efficacy Before Thrombectomy in Acute Large-Vessel Occlusion Stroke: A Post Hoc Analysis of the BRIDGE-TNK Randomized Trial Neurology, 2026-09-22 DOI, PubMed 42623571
  • Intravenous Tenecteplase before Thrombectomy in Stroke The New England journal of medicine, 2025-07-10 DOI, PubMed 40396577

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04733742. Randomized; single masking; primary purpose treatment. Start 2022-05-09 (actual); primary completion 2024-12-16 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Endovascular Treatment With Versus Without Intravenous rhTNK-tPA in Stroke
Acronym
BRIDGE-TNK
Condition
Stroke, Acute
Condition
Stroke, Ischemic
Intervention (Drug)
rhTNK-tPA
Intervention (Other)
Endovascular treatment
Lead sponsor
Xinqiao Hospital of Chongqing (class: other)
Collaborator
CSPC RECOMGEN PHARMACEUTICAL (GUANGZHOU) CO.,LTD (class: not stated)

Record details

Record id
cardio:ct-nct04733742
Content hash
b81f0ad0656fd9fe02390b8acb9f53b76fbca1b32f03288090e80937e56651ff